Converting the Dissatisfied

Ironwood Pharmaceuticals (Nasdaq: IRWD  ) Linzess got the early FDA approvals flowing this week.

Yesterday, the biotech announced that the FDA had approved Linzess, its treatment for irritable bowel syndrome. The PDUFA date for the drug wasn't until Sep. 8. Of course, the FDA took an extra three months to review some additional data it requested; so, perhaps finishing early, especially right before a three-day weekend, shouldn't be all that surprising.

Ironwood and partner Forest Labs (NYSE: FRX  ) plan to launch the drug in Dec., after the companies get feedback from the FDA on their promotional materials. The holiday season seems like an inopportune time to launch a drug, but Forest said it's had good results with launching around that time of the year. Perhaps "get a better drug to treat my IBD" will be on some people's New Year's resolution list.

The key for a quick launch is to capture patients who are dissatisfied with current treatments. Ironwood and Forest think there are potentially 10 million patients that fit into that category.

Most patients are taking over-the-counter medications, like Procter & Gamble's (NYSE: PG  ) Metamucil or Novartis' (NYSE: NVS  ) ex-lax. In theory, converting OTC patients to prescription patients is difficult, because it's more convenient to try something else on the pharmacy shelf than head to the doctor's office. But Ironwood thinks these patients are so desperate to find something that works, that they're seeing their doctor on a regular basis anyway.

As an example of how the conversion could potentially work, the companies cite AstraZeneca (NYSE: AZN  ) , which was successful getting patients off OTC antacids and onto prescription Prilosec when it launched.

At a market cap of$1.3 billion, investors don't appear to be expecting a very fast launch. With an approval in hand, Ironwood looks like a fairly low-risk stock at this price, with a potential kicker if Linzess can get out of the gates faster than expected. Be sure to follow these companies by adding them to your free personalized watchlist.  

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Procter & Gamble. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 01, 2012, at 2:46 AM, MBfool wrote:

    You meant IBS (Irritable Bowel Syndrome). Not IBD (Inflammatory Bowel Disease).

    IBS is not simple constipation and indeed IBS is the most common diagnosis in gastroenterologists’ practices, accounting for an estimated 25% of all gastroenterology patients. IBS accounts for 12% of patient visits to primary care physicians.

    So, it is not so much about converting from OTC to a prescription medicine, but, providing more effective therapy to the IBS patients that are already in the doctors' office.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2003781, ~/Articles/ArticleHandler.aspx, 11/26/2014 7:18:20 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement